Morgan Samet
Managing Partner & Co-Head @ Lingotto Innovation @ Lingotto
New York, United States
Morgan Samet is a Series B investor at Lingotto in New York focused on Biotechnology and Energy. Morgan Samet
- Total investments:
- 7
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Morgan Samet invests in
Stages Morgan Samet invests in
Countries Morgan Samet invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 2 (29%)
- Energy 1 (14%)
- Medical 1 (14%)
- Robotics 1 (14%)
- Software 1 (14%)
Stage
- Series B 2 (29%)
- Series C 2 (29%)
- Series D 1 (14%)
- Series G 1 (14%)
- Venture - Series Unknown 1 (14%)
Country
- United States 2 (29%)
- Sweden 1 (14%)
- Germany 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
RobCo
|
RobCo is a company that develops modular industrial robotics systems combined with AI-driven software to automate manual and repetitive tasks in manufacturing environments. It provides a platform that includes configurable robotic hardware, no-code programming tools, AI-powered vision systems, and digital simulation to plan, test, and deployautomation workflows across applications like machine loading, palletizing, and materials handling. The company’s solutions are designed to be flexible and scalable so manufacturers can adapt robot configurations as production requirements evolve. RobCo also offers tools for remote management, predictive maintenance, and integration with existing equipment to support continuous operation. Its products aim to simplify the adoption of robotics by reducing the need for specialized programming and enabling simulation-based validation before physical deployment. | $100M / Series C / Jan 29, 2026 | |
Enveda Biosciences
|
Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California. | $150M / Series D / Sep 04, 2025 | |
Aira
|
Aira operates as a clean energy-tech company. | $174.3M / Venture - Series Unknown / Aug 11, 2025 | |
|
Enveda Biosciences
|
Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California. | $130M / Series C / Nov 21, 2024 | |
|
Enveda Biosciences
|
Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California. | $55M / Series B / Jun 14, 2024 | |
|
Aira
|
Aira operates as a clean energy-tech company. | $158.7M / Series B / Jan 15, 2024 | |
Tempus
|
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions todeliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. | Series G / Oct 12, 2023 |
Co-Investors
About Lingotto
Lingotto is an investment management company owned by Exor N.V. and launched by the Italian dynasty the Agnelli family.The company possesses a set of distinctive competitive edges that distinguish it in the market. One key strength lies in its unique investment strategies, which are complementary, differentiated, and unparalleled, providing acompetitive advantage over its peers. Moreover, the company has fostered a culture of partnership, promoting autonomy and cooperation among its stakeholders. This collaborative approach not only enhances teamwork but also strengthens relationships within the organization. Another significant aspect of the company's operations is its unwavering commitment to accountability, integrity, and transparency, ensuring a high level of trust and reliability for its clients and partners.
Lingotto Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Morgan Samet
Managing Partner & Co-Head @ Lingotto Innovation
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Morgan Samet invest in?
Morgan Samet invests primarily in Biotechnology, Energy and Medical startups, most often at Series B and Series C stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Morgan Samet?
Public channels for Morgan Samet include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Morgan Samet last invest?
The most recent investment recorded for Morgan Samet closed in Jan 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
